+86-27-65522453 sales@sun-shinechem.com

Capivasertib (AZD5363)

Catalog No.: 71805
Cas No.: 1143532-39-1
Purity : 98% by HPLC 
71805 - Capivasertib (AZD5363) | CAS 1143532-39-1

Catalog number : 71805

CAS number : 1143532-39-1

分子式 : C21H25ClN6O2 

分子量 : 428.92 

Iupac 化学名称 : 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide 

Smile : O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO


PackagingPriceAvailabilityPurityEstimated Shipping Time
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词AZD5363; AZD-5363; AZD 5363; Capivasertib
英文同义词AZD5363; AZD-5363; AZD 5363; Capivasertib
外观crystalline solid 
纯度98% by HPLC 
可溶性Soluble in DMSO 
存储3 years -20ºCpowder 6 months-80ºCin solvent 
运输条件Shipped under ambient temperature 
Coming soon.


is a  novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers. Check for active clinical trials using this agent. (NCI Thesaurus)


[1]. Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012 Apr;11(4):873-87.

1143532-39-1 - Request Bulk Quote

1143532-39-1 - Request Bulk Quote